Aigen Investment Management, LP Ironwood Pharmaceuticals Inc Transaction History

Aigen Investment Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$8.79 - $11.51 $68,852 - $90,157	7,833 Added 58.29%	21,270 $243,000
Q3 2023 Nov 13, 2023	BUY	$8.25 - $11.35 $110,855 - $152,509	13,437 New	13,437 $129,000
Q1 2023 May 15, 2023	SELL	$10.37 - $12.56 $95,341 - $115,476	-9,194 Reduced 22.38%	31,893 $335,000
Q4 2022 Feb 10, 2023	BUY	$9.9 - $12.43 $406,761 - $510,711	41,087 New	41,087 $509,000
Q1 2022 May 05, 2022	SELL	$10.61 - $12.88 $142,789 - $173,339	-13,458 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$10.86 - $13.95 $146,153 - $187,739	13,458 New	13,458 $157,000
Q3 2020 Nov 06, 2020	SELL	$8.99 - $10.74 $185,023 - $221,039	-20,581 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$9.14 - $11.97 $437,230 - $572,608	-47,837 Reduced 69.92%	20,581 $212,000
Q1 2020 May 08, 2020	SELL	$8.58 - $14.01 $139,922 - $228,475	-16,308 Reduced 19.25%	68,418 $690,000
Q4 2019 Feb 04, 2020	BUY	$8.22 - $14.0 $696,447 - $1.19 Million	84,726 New	84,726 $1.13 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $530M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.